randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA

randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA - randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000155

Enrollment

100

Registered

2005-10-01

Start date

2002-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

docetaxel and carboplatin weekly paclitaxel and carboplatin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with histologically or cytologically confirmed epitheral ovarian cancer, fallopian tubal cancer or peritoneal cancer. performance status(ECOG)0-2. no prior chemotherapy. adequate levels of bone marrow,hepatic,and renal function. n. no heart failure and pulmonary disease. no active infection. no other malignancies. signing of an informed consent document.

Exclusion criteria

Exclusion criteria: pregnant or nursing woman

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Secondary

Measure	Time frame
quality of life ,safety	—

Countries

Japan

Contacts

Public ContactKenichi Hosokawa

Kyoto Prefectual University department of obstetrics and gynecology

hosokawa@koto.kpu-m.ac.jp075-251-5560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026